Last reviewed · How we verify
recombinant HIV-1 Tat protein — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
recombinant HIV-1 Tat protein (recombinant HIV-1 Tat protein) — Istituto Superiore di Sanità.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| recombinant HIV-1 Tat protein TARGET | recombinant HIV-1 Tat protein | Istituto Superiore di Sanità | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- recombinant HIV-1 Tat protein CI watch — RSS
- recombinant HIV-1 Tat protein CI watch — Atom
- recombinant HIV-1 Tat protein CI watch — JSON
- recombinant HIV-1 Tat protein alone — RSS
Cite this brief
Drug Landscape (2026). recombinant HIV-1 Tat protein — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-hiv-1-tat-protein. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab